Oncology On nuclear medicine and oncology, SHINE Technologies Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
Digital Unicorns, AI, and the future of health: Highlights from HLTH... Deep Dive editor Eloise McLennan debriefs on the key themes, hot topics, and hallway conversations that shaped the HLTH event in Amsterdam.
Patients On patient-centric treatment decisions and the value of quan... Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, discusses the pressing need for quantitative methodologies.
R&D Maximising value by uniting the digital backbone: On a new N... Novo Nordisk and Veeva have entered into a new partnership for clinical development.
Market Access The changing landscape of drug clinical assessment: Tommy Br... In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.